SIFI

SIFI TO PRESENT NEW SCIENTIFIC DATA AND LAUNCH A NEW INTRAOCULAR LENS DURING THE 40TH CONGRESS OF THE EUROPEAN SOCIETY OF CATARACT AND REFRACTIVE SURGEONS

Retrieved on: 
Thursday, September 15, 2022
Well, Ocular hypertension, Lens (anatomy), Glaucoma, Netilmicin, European Society for Medical Oncology, Ophthalmology, Patient, Presbyopia, Cataract, Quality of life, WELL, Acid-free paper, Dexamethasone, Mini, SIFI, Veterinary medicine, Telescopic sight, IOL

These presentations will feature the results of studies evaluating SIFI's advanced solutions for cataract refractive surgery.

Key Points: 
  • These presentations will feature the results of studies evaluating SIFI's advanced solutions for cataract refractive surgery.
  • Evolux was developed on a patented technology platform, pioneering the extension of the depth of focus through wavefront engineering.
  • The E-poster "Evolux, The New Standard Of Care With Extended Depth Of Focus In Monofocal Intraocular Lenses".
  • SIFI is a leading international ophthalmic company, headquartered in Italy, focusing on eye care since 1935.

SIFI TO PRESENT NEW SCIENTIFIC DATA AND LAUNCH A NEW INTRAOCULAR LENS DURING THE 40TH CONGRESS OF THE EUROPEAN SOCIETY OF CATARACT AND REFRACTIVE SURGEONS

Retrieved on: 
Thursday, September 15, 2022
Well, Ocular hypertension, Lens (anatomy), Glaucoma, Netilmicin, European Society for Medical Oncology, Ophthalmology, Patient, Presbyopia, Cataract, Quality of life, WELL, Acid-free paper, Dexamethasone, Mini, SIFI, Veterinary medicine, Telescopic sight, IOL

These presentations will feature the results of studies evaluating SIFI's advanced solutions for cataract refractive surgery.

Key Points: 
  • These presentations will feature the results of studies evaluating SIFI's advanced solutions for cataract refractive surgery.
  • Evolux was developed on a patented technology platform, pioneering the extension of the depth of focus through wavefront engineering.
  • The E-poster "Evolux, The New Standard Of Care With Extended Depth Of Focus In Monofocal Intraocular Lenses".
  • SIFI is a leading international ophthalmic company, headquartered in Italy, focusing on eye care since 1935.

Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy

Retrieved on: 
Friday, July 8, 2022
Weight gain, Patient, GLOBE, Retina, Cancer, AIFA, Osteoporosis, Uveitis, Recurrence, Injection, Alimera Sciences, Analysis, SIFI, Organization, Financial condition report, SEC, Result, Associate, Eye, Lists of countries and territories, Inflammation, Lists of diseases, DME, Severe cognitive impairment, Infection, Private Securities Litigation Reform Act, Sleep, Italian Medicines Agency, Hypertension, Mutual, Diabetic retinopathy, News, Acne, Annual report, Vita-Salute San Raffaele University, Disease, Compte rendu, Risk, Fluocinolone acetonide, Intraocular pressure, Physician, European Medicines Agency, Pharmaceutical industry, Trosia

Alimera will launch ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant behind its new uveitis indication in Italy, through its distribution partner, SIFI.

Key Points: 
  • Alimera will launch ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant behind its new uveitis indication in Italy, through its distribution partner, SIFI.
  • The Companys primary product is ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant, injected into the back of the eye.
  • In March 2019, ILUVIEN received approval in the 17 countries under the Mutual Recognition Procedure for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
  • Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf.

SIFI ANNOUNCES EMA VALIDATION OF ITS MARKETING AUTHORISATION APPLICATION FOR AKANTIOR® FOR THE TREATMENT OF ACANTHAMOEBA KERATITIS AND THE OPENING OF AN EARLY ACCESS PROGRAM

Retrieved on: 
Tuesday, June 7, 2022
Severe cognitive impairment, Marketing, Leadership, Eye, Company, Acanthamoeba keratitis, Research, EMA, EC, UCL Institute of Ophthalmology, Standard of care, Transplant, University College London, Disease, CEO, Committee, European Directive on Traditional Herbal Medicinal Products, Partnership, Trophozoite, CHMP, Medicines and Healthcare products Regulatory Agency, Patient, Fungal keratitis, SIFI, EAPS, Committee for Medicinal Products for Human Use, Polyhexanide, Phase, Medication, Incidence, Quality of life, European Medicines Agency, Royal commission, European Commission, Drug development, West Pharmaceutical Services, Marketing Authorisation Application, Institute, AK, Cyst, Medical device, Pharmaceutical industry, Acanthamoeba, Ophthalmology

"We are incredibly pleased to be working in partnership with SIFI on this important access program," said Dan Piggott, Managing Director of Uniphar Group's Product Access Division.

Key Points: 
  • "We are incredibly pleased to be working in partnership with SIFI on this important access program," said Dan Piggott, Managing Director of Uniphar Group's Product Access Division.
  • "We look forward to helping facilitate broader access to polihexanide for patients with critical unmet medical needs suffering from acanthamoeba keratitis."
  • AKANTIOR (polihexanide) stands to become the first approved drug for the treatment of acanthamoeba keratitis in the world.
  • Polihexanide is also being developed by SIFI for the treatment of fungal keratitis for which indication it also has FDA Orphan Drug Designation.

SIFI ANNOUNCES EMA VALIDATION OF ITS MARKETING AUTHORISATION APPLICATION FOR AKANTIOR® FOR THE TREATMENT OF ACANTHAMOEBA KERATITIS AND THE OPENING OF AN EARLY ACCESS PROGRAM

Retrieved on: 
Tuesday, June 7, 2022
Severe cognitive impairment, Marketing, Leadership, Eye, Company, Acanthamoeba keratitis, Research, EMA, EC, UCL Institute of Ophthalmology, Standard of care, Transplant, University College London, Disease, CEO, Committee, European Directive on Traditional Herbal Medicinal Products, Partnership, Trophozoite, CHMP, Medicines and Healthcare products Regulatory Agency, Patient, Fungal keratitis, SIFI, EAPS, Committee for Medicinal Products for Human Use, Polyhexanide, Phase, Medication, Incidence, Quality of life, European Medicines Agency, Royal commission, European Commission, Drug development, West Pharmaceutical Services, Marketing Authorisation Application, Institute, AK, Cyst, Medical device, Pharmaceutical industry, Acanthamoeba, Ophthalmology

"We are incredibly pleased to be working in partnership with SIFI on this important access program," said Dan Piggott, Managing Director of Uniphar Group's Product Access Division.

Key Points: 
  • "We are incredibly pleased to be working in partnership with SIFI on this important access program," said Dan Piggott, Managing Director of Uniphar Group's Product Access Division.
  • "We look forward to helping facilitate broader access to polihexanide for patients with critical unmet medical needs suffering from acanthamoeba keratitis."
  • AKANTIOR (polihexanide) stands to become the first approved drug for the treatment of acanthamoeba keratitis in the world.
  • Polihexanide is also being developed by SIFI for the treatment of fungal keratitis for which indication it also has FDA Orphan Drug Designation.

Harbor Capital Advisors to Expand ETF Suite with International Compounders ETF

Retrieved on: 
Thursday, May 19, 2022
Professional Services, Finance, Risk, THIS, WINN, ETF, Investment, Goal, ANY, Solution, SIFI, CIO, Philosophy, Orientation, NOR, RISKS, AND, Canyon Capital Advisors, SELL, CITS-DT, SEC, Harbor, Fund, Growth, LLC, TIME, ESG, Financial adviser, Security (finance), Risk management

Harbor Capital Advisors, Inc. (Harbor), today announced that it is adding to its exchange-traded fund (ETF) lineup, bringing a new active and fully transparent Harbor International Compounders ETF (OSEA) to market in early September, upon completion of the registration process.

Key Points: 
  • Harbor Capital Advisors, Inc. (Harbor), today announced that it is adding to its exchange-traded fund (ETF) lineup, bringing a new active and fully transparent Harbor International Compounders ETF (OSEA) to market in early September, upon completion of the registration process.
  • We are excited to launch the Harbor International Compounders ETF, providing clients with an active, concentrated & fully transparent ETF focused on international companies with expected sustainable earnings growth to help drive compounded long-term wealth creation.
  • Harbor International Compounders ETF (OSEA) will pursue an actively managed strategy that seeks long-term growth of capital and invests primarily in equity securities of non-U.S. companies, including those located in emerging market countries.
  • Harbor currently has six ETFs: Harbor All-Weather Inflation ETF (HGER) , Harbor Long-Term Growers ETF (WINN) , Harbor Corporate Culture Leaders ETF (HAPY) , Harbor Disruptive Innovation ETF (INNO) , Harbor Scientific Alpha Income ETF (SIFI) , and Harbor Scientific Alpha High Yield ETF (SIHY) .

SIFI RECEIVES FAVORABLE FEEDBACK FROM THE US FDA ON AKANTIOR® FOR THE TREATMENT OF ACANTHAMOEBA KERATITIS

Retrieved on: 
Monday, May 16, 2022
Company, Disease, Polyhexanide, Acanthamoeba keratitis, Eye, Incidence, NCE, Cyst, Patient, Quality of life, Severe cognitive impairment, SIFI, Research, Patent, FDA, Trophozoite, Massachusetts Eye and Ear, Transplant, University, Orphan, NDA, American Journal, Illinois Eye and Ear Infirmary, AK, The Company, Ophthalmology, MD, Fungal keratitis, CEO, Pharmaceutical industry, Acanthamoeba, New chemical entity

ABOUT AKANTIOR: AKANTIOR (polihexanide) stands to become the first approved drug for the treatment of acanthamoeba keratitis in the world.

Key Points: 
  • ABOUT AKANTIOR: AKANTIOR (polihexanide) stands to become the first approved drug for the treatment of acanthamoeba keratitis in the world.
  • Polihexanide is also being developed by SIFI for the treatment of fungal keratitis for which indication it also has FDA Orphan Drug Designation.
  • ABOUT Acanthamoeba Keratitis (AK): AK is a rare, acute, severe parasitic corneal infection caused by Acanthamoeba, a free-living amoeba.
  • ABOUT SIFI: SIFI is a leading international ophthalmic company, headquartered in Italy, focusing on eye care since 1935.

SIFI RECEIVES FAVORABLE FEEDBACK FROM THE US FDA ON AKANTIOR® FOR THE TREATMENT OF ACANTHAMOEBA KERATITIS

Retrieved on: 
Monday, May 16, 2022
Company, Disease, Polyhexanide, Acanthamoeba keratitis, Eye, Incidence, NCE, Cyst, Patient, Quality of life, Severe cognitive impairment, SIFI, Research, Patent, FDA, Trophozoite, Massachusetts Eye and Ear, Transplant, University, Orphan, NDA, American Journal, Illinois Eye and Ear Infirmary, AK, The Company, Ophthalmology, MD, Fungal keratitis, CEO, Pharmaceutical industry, Acanthamoeba, New chemical entity

ABOUT AKANTIOR: AKANTIOR (polihexanide) stands to become the first approved drug for the treatment of acanthamoeba keratitis in the world.

Key Points: 
  • ABOUT AKANTIOR: AKANTIOR (polihexanide) stands to become the first approved drug for the treatment of acanthamoeba keratitis in the world.
  • Polihexanide is also being developed by SIFI for the treatment of fungal keratitis for which indication it also has FDA Orphan Drug Designation.
  • ABOUT Acanthamoeba Keratitis (AK): AK is a rare, acute, severe parasitic corneal infection caused by Acanthamoeba, a free-living amoeba.
  • ABOUT SIFI: SIFI is a leading international ophthalmic company, headquartered in Italy, focusing on eye care since 1935.

Harbor Capital Advisors Partners with TIFIN's AI-Powered Digital Distribution Solutions to Transform the Asset Management Industry

Retrieved on: 
Tuesday, April 12, 2022
Risk, Face, Investment, Growth, Multimedia, Fund, AND, Distillation, FUND, THIS, RISKS, CEO, Harbor, Intelligence, ETF, Science and technology in Asia, Screen magnifier, SIFI, View, Canyon Capital Advisors, Artificial intelligence, Industry, Technology, WINN, Goal, Solution, AI, Financial adviser, Cryptocurrency

BOULDER, Colo., April 12, 2022 /PRNewswire/ -- TIFIN, a fintech platform using Artificial Intelligence (AI) and investment-driven personalization to assist asset managers with their digital distribution, announced that Distill by TIFIN is partnering with Harbor Capital Advisors (Harbor), a premier investment firm offering access to a range of investment solutions, to provide real-time digital solutions seeking to better engage with clients. 

Key Points: 
  • Asset managers are able to curate communication proposals by offering investment products that fit their clients' goals resulting in faster conversions.
  • "We recognize that the asset management industry is shifting towards digital distribution of investment products, and we need to embrace a purposeful way to connect with clients," said Charles McCain, CEO of Harbor Capital Advisors.
  • "By partnering with Distill, asset managers will get actionable and targeted ai-driven insights to drive flows, product design and capital decisions.
  • Harbor recently launched a series of fully transparent ETFs providing advisors and investors new ways to access exclusive investment management solutions to achieve long-term investment goals.

SIFI Announces the Granting of a Second FDA Orphan Drug Designation for Polihexanide in Fungal Keratitis

Retrieved on: 
Monday, March 14, 2022
University, Acanthamoeba keratitis, Incidence, Fungal keratitis, Mazzone, Business, Risk, Company, III, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Quality of life, Person, EMA, Severe cognitive impairment, DNA, PDUFA, Patient, Marketing, European Medicines Agency, SIFI, Infection, Disease, Food, ODD, Program, Diagnosis, Pharmaceutical industry, Ophthalmology, Lancet

According to The Lancet , annual global incidence of fungal keratitis is estimated at 1,051,787 cases, with the highest rates in Asia and Latin America.

Key Points: 
  • According to The Lancet , annual global incidence of fungal keratitis is estimated at 1,051,787 cases, with the highest rates in Asia and Latin America.
  • In the U.S., an estimated 15,660 patients annually most of whom are contact lens wearers or agricultural workers are diagnosed with fungal keratitis.
  • Only one drug is currently approved for fungal keratitis in the U.S., and around one in three patients fail on the treatment.
  • Brown L., Leck AK, Gichangi M, Burton MJ, Denning DW, The global incidence and diagnosis of fungal keratitis.